BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of Brequinar sodium (NSC 368390; DUP 785) in cerebrospinal fluid. 1988

G Schwartsmann, and W J van der Vijgh, and I Klein, and C J van Groeningen, and J B Vermorken, and H M Pinedo

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009669 Nose Neoplasms Tumors or cancer of the NOSE. Cancer of Nose,Nasal Neoplasms,Nose Cancer,Cancer of the Nose,Nasal Cancer,Neoplasms, Nose,Cancer, Nasal,Cancer, Nose,Cancers, Nasal,Cancers, Nose,Nasal Cancers,Nasal Neoplasm,Neoplasm, Nasal,Neoplasm, Nose,Neoplasms, Nasal,Nose Cancers,Nose Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001713 Biphenyl Compounds Whitish aromatic crystalline organic compounds made up of two conjoined BENZENE rings. Compounds, Biphenyl
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

G Schwartsmann, and W J van der Vijgh, and I Klein, and C J van Groeningen, and J B Vermorken, and H M Pinedo
Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
August 1989, Cancer research,
G Schwartsmann, and W J van der Vijgh, and I Klein, and C J van Groeningen, and J B Vermorken, and H M Pinedo
Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patients.
January 1993, European journal of cancer (Oxford, England : 1990),
G Schwartsmann, and W J van der Vijgh, and I Klein, and C J van Groeningen, and J B Vermorken, and H M Pinedo
Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer.
January 1990, Biochemical pharmacology,
G Schwartsmann, and W J van der Vijgh, and I Klein, and C J van Groeningen, and J B Vermorken, and H M Pinedo
The relationship between dihydroorotic acid dehydrogenase and in vitro and in vivo cytostatic effects of brequinar sodium (DUP-785; NSC 368390).
January 1989, Advances in experimental medicine and biology,
G Schwartsmann, and W J van der Vijgh, and I Klein, and C J van Groeningen, and J B Vermorken, and H M Pinedo
A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule.
October 1989, European journal of cancer & clinical oncology,
G Schwartsmann, and W J van der Vijgh, and I Klein, and C J van Groeningen, and J B Vermorken, and H M Pinedo
In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine.
February 1992, British journal of cancer,
G Schwartsmann, and W J van der Vijgh, and I Klein, and C J van Groeningen, and J B Vermorken, and H M Pinedo
Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390).
January 1987, Investigational new drugs,
G Schwartsmann, and W J van der Vijgh, and I Klein, and C J van Groeningen, and J B Vermorken, and H M Pinedo
Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.
January 1998, Investigational new drugs,
G Schwartsmann, and W J van der Vijgh, and I Klein, and C J van Groeningen, and J B Vermorken, and H M Pinedo
DUP 785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects.
September 1988, Biochemical pharmacology,
G Schwartsmann, and W J van der Vijgh, and I Klein, and C J van Groeningen, and J B Vermorken, and H M Pinedo
Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
August 1990, Cancer research,
Copied contents to your clipboard!